Wyeth and Ambrx Form Multi-target Alliance to Leverage Recent Ambrx Biologics Platform Advances

Wyeth and Ambrx Form Multi-target Alliance to Leverage Recent Ambrx Biologics Platform Advances
Ambrx Inc. 
 
tool goes here COLLEGEVILLE, Pa. and SAN DIEGO, Sept. 18 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Ambrx Inc. today announced the formation of a worldwide alliance to discover, develop, and commercialize protein drug candidates for three undisclosed targets in multiple therapeutic areas. The alliance will capitalize on Ambrx's recent breakthroughs in applying its protein medicinal chemistry platform to proteins produced in mammalian cells such as antibodies and antibody-toxin conjugates.

Ambrx anticipates earning near term payments from an upfront commitment, target loading fees and research funding. In addition, Ambrx will be eligible to receive escalating preclinical, clinical, regulatory and commercial milestone payments as well as tiered royalties on sales of products resulting from the collaboration.

"This collaboration with Ambrx reinforces Wyeth's commitment to sustaining and growing our already robust capabilities in the field of biologics drug discovery through partnerships with biotech innovators," said Mikael Dolsten, M.D., Ph.D., President, Wyeth Research. "We are enthusiastic about working with Ambrx, a company with the ability to create and advance precisely engineered biologic drug candidates into clinical trials using its proprietary platform."

Stephen Kaldor, Ph.D., President and CEO of Ambrx, said: "Wyeth is a long-standing leader in protein therapeutics with a strong record of successfully developing innovative products. We are pleased that Wyeth recognizes the power of the Ambrx EuCODE(TM) platform and look forward to collaborating with Wyeth's talented personnel to produce the next generation of biologic drugs."

About Ambrx

Ambrx Inc. is a clinical stage biopharmaceutical company with a broad biologics platform that allows it to create best-in-class therapeutics, including improved versions of native proteins and therapeutic antibodies. Its most advanced product candidate, ARX201, is a long-acting growth hormone partnered with Merck Serono that has successfully completed initial clinical trials. The company has further validated its biologics platform through additional partnerships with Merck Serono, Eli Lilly and Company and Merck & Co. Ambrx is advancing a robust portfolio of product opportunities spanning multiple therapeutic areas that are high optimized for efficacy, safety and ease of use. For additional information, visit www.ambrx.com.

About Wyeth

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines, and nutritional products. Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.